August 8, 2019

Oncternal Reports Second Quarter 2019 Financial Results and Provides Business Update

August 7, 2019

Retrotope Announces Full Enrollment of Phase 2/3 trial in patients with Infantile Neuroaxonal Dystrophy (INAD)

July 19, 2019

Retrotope Announces Completion of Series C Preferred Financing and Addition of a Lead Investor on the Board of Directors

June 10, 2019

Oncternal Therapeutics Completes Reverse Merger with GTx, Inc.

May 31, 2019

selectION, Inc. Announces $4.1M Series A Investment

May 7, 2019

Retrotope Announces RT001 Clinical Data Presentation at the 2019 American Academy of Neurology (AAN) Annual Meeting

March 13, 2019

EMA Grants Orphan Medicinal Product Designation for Retrotope’s RT001 in the Treatment of Infantile Neuroaxonal Dystrophy (INAD), a PLA2G6 associated neurodegeneration (PLAN)

March 7, 2019

GTx and Oncternal Therapeutics Enter into Definitive Merger Agreement

January 3, 2019

Immusoft Raises $20 Million In Series B Financing

December 13, 2018

Retrotope Announces First Dosing of RT001 in patients with Infantile Neuroaxonal Dystrophy (INAD)